In this work, a “psoriasis catalytic therapy” strategy has been introduced to ameliorate psoriatic lesions and prevent its recurrence by designing catalytically active biomimetic materials (FeN4O2-SACs) possessing multiple CAT-, SOD- and APX-like activities to continuously scavenge overexpressed ROS. The gene discussed is SOD1; the disease is psoriasis.